Continuing Education
Pharmacogenomics Overview and Tumor Agnostic Approvals
Best Suited For: Pharmacist, Pharmacy Technician
CE Credits: 1 hours
Activity Description
This activity provides an overview of pharmacogenomics and precision oncology testing in cancer care, focusing on mutation terminology, appropriate use of next-generation sequencing, and the clinical implications of tumor-agnostic biomarkers and associated therapies.
CE Credit: 1 hour
Fee: This activity does not require payment to register.
Learning Objectives
- Explain pharmacogenomics and the history around testing in cancer care.
- Differentiate common mutation types in cancer and the methods used for naming them.
- Discuss the rationale for NGS testing and appropriate candidate selection for NGS testing.
- Review tumor agnostic approvals, including MSI-H, dMMR, TMB, NTRK fusions, RET-fusions, HER2-positive (IHC3+) and BRAF V600E mutation.
- Recognize common toxicities associated with therapies used in tumor agnostic approvals.
Obtaining CE Credit
To receive credit, you must and complete all the steps found in the “Complete Credit Requirements” link provided by the registration confirmation email from LecturePanda You may also use this page to obtain CE credit. After following the link on this page to in order to receive credit:
- Reviewing the course learning materials.
- Confirming information provided on registration.
- Watching the CE video (if it is an enduring or on-demand CE activity) to its entirety
- Submitting the CE Code (disclosed towards the end of all CE activities)
- Completing all listed evaluations and CE assessments.
Credit requirements must be completed before the date of the activity. Upon completion, credit will be transmitted electronically to the ACPE. All transmitted will be viewable in your CPE Monitor profile within 24 hours.
